Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
Background: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) after previous failed gemcitabine-based therapy. This population-based study aimed to evaluate the efficac...
Saved in:
Main Authors: | Tai-Jan Chiu, Yung-Yeh Su, Shih-Hung Yang, Chung-Pin Li, Li-Yuan Bai, Nai-Jung Chiang, Shih-Chang Chuang, Yan-Shen Shan, De-Chuan Chan, Li-Tzong Chen, Chia-Jui Yen, Cheng-Ming Peng, Yen-Yang Chen, Jen-Shi Chen, Wen-Chi Chou |
---|---|
Format: | article |
Language: | EN |
Published: |
SAGE Publishing
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/4f0d6e13c91c49d18e9d3d1591cc40a2 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
by: Wu H, et al.
Published: (2015) -
Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum]
by: Wu H, et al.
Published: (2019) -
Albuminuria Pre-Emptively Identifies Cardiac Patients at Risk of Contrast-Induced Nephropathy
by: Laura Vicente-Vicente, et al.
Published: (2021) -
Acta Nº667
by: Banco Central de Chile
Published: (2019) -
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
by: Se Jun Park, et al.
Published: (2021)